(Q43503224)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

title

Single agent epirubicin as first line chemotherapy for metastatic breast cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

1 reference

metastatic breast cancer

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Pierfranco Conte

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

A Michelotti

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

M Venturini

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

C Tibaldi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

C Bengala

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

L Gallo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

F Carnino

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

R Lionetto

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

E Montanaro

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

R Rosso

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

language of work or name

English

0 references

publication date

1 January 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

59

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

133-139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10817348%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1006394801389

6 November 2019

exact match

0 references

cites work

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

Drugs ten years later: epirubicin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

The calculation of actual or received dose intensity: a comparison of published methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

Conventional versus high-dose epidoxorubicin as single agent in advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

7 January 2021

Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

7 January 2021

Epirubicin at two dose levels with prednisolone as treatment for advanced breast cancer: the results of a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

7 January 2021

Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

7 January 2021

Epirubicin + G-CSF as peripheral blood progenitor cells (PBPC) mobilising agents in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

7 January 2021

Pharmacokinetics of taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

7 January 2021

Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

7 January 2021

Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1006394801389

7 January 2021